Renal Cell Carcinoma
Online Inquiry

Renal Cell Carcinoma

Renal cell carcinoma (RCC) is an extremely challenging disease. It poses a major threat to human health, with the incidence increasing at a rate of about 2% per year. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we can provide the best vaccine development services for renal cell carcinoma.

Introduction to Renal Cell Carcinoma

As is well known, RCC has unique biological behaviors. The host immune system plays an important role in the immune response mediated by tumor rejection cells. Therefore, active and passive immunotherapy, as well as specific and non-specific immunotherapy, are suitable alternative options for treating RCC.

Traditional Therapy for Renal Cell Carcinoma

Therapies of renal cell carcinoma remain palliative. Compared with cytokines and chemotherapy, targeted therapy improves response rates and prolongs overall survival and progression-free survival. In addition, checkpoint inhibitors constitute an update of the therapeutic approach, while anti-PD-1 antibodies, a checkpoint inhibitor, are now identified as a therapy for renal cell carcinoma, but high toxicity and cost are limiting factors. Immunotherapy will continue to play an important role in the therapy of renal cell carcinoma.

New Therapy for Renal Cell Carcinoma

Based on a deep understanding of immune mechanisms, new immunotherapies are rapidly developing. Therapeutic cancer vaccines target tumor antigens and adjuvant molecules that trigger specific antibodies or cytotoxic immune responses against cancer cells.

Multi-Epitope Vaccine Development

Given the high heterogeneity of renal cell carcinoma, the specific antigens in tumor lysates are quite different from the widely studied tumor-associated antigens. To ensure the effectiveness of cancer vaccines, it is necessary to develop multi-epitope or personalized epitope renal cell carcinoma vaccines.

Extracellular Vesicles Vaccine Development

Extracellular vesicles (EVs) are small, membrane-wrapped nanoparticles that are intentionally released by the cell into the extracellular environment. EVs contain a variety of bioactive compounds, such as proteins, nucleic acids, and lipids, which can be taken up by various cells and have various regulatory effects.

  • Intercellular communication
  • Involved in immune escape
  • Mediates epithelial-mesenchymal transformation
  • Stimulate angiogenesis
  • Enhance the resistance mechanism
  • Promote proliferation, invasion, and migration
Therefore, the prospect of EVs-based renal cell carcinoma vaccines is promising.

Our Service

Depending on the form of the antigen, there are several ways of delivering antigens to the immune system. Alfa Cytology provides various renal cell carcinoma vaccine development services.

The field of immuno-oncology is growing rapidly. Cancer vaccine is an important strategy for metastatic renal cell carcinoma. Here are the types of cancer vaccines we can develop, including but not limited to the following.

Immunotherapy is rapidly changing the therapy landscape for many cancers, including renal cell carcinoma. Alfa Cytology is committed to the research and development of cancer vaccines, from the discovery of cancer antigens, and the development of different types of vaccines, to vaccine research for different cancer types, providing one-stop services. If you are interested in our service, please contact us.

 For Research Only.